AMLX Amylyx Pharmaceuticals, Inc.

NASDAQ
$27.62

Amylyx Pharmaceuticals, Inc. (AMLX) is confirmed to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.37 per share.

Amylyx Pharmaceuticals Reported In-line with Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.37)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $32.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments.

Sector

Healthcare

Industry

Biotechnology

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.